Decreased expression of hepatic glucokinase in type 2 diabetes

Molecular Metabolism

Volumn 4, Issue 3, 2015, Pages 222-226

  Haeusler, Rebecca A ^a   Camastra, Stefania ^b   Astiarraga, Brenno ^b   Nannipieri, Monica ^b   Anselmino, Marco ^c   Ferrannini, Ele ^b,d  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Diabetes; Glucokinase; Humans

Indexed keywords

GLUCOKINASE; GLUCOSE 6 PHOSPHATASE; HEMOGLOBIN A1C; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; PHOSPHOENOLPYRUVATE CARBOXYKINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; LIVER LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TISSUE DISTRIBUTION; UPREGULATION;

ANIMALIA;

EID: 84924074482     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.12.007     Document Type: Article

References (30)

1. Boden G., Chen X., Stein T.P. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. American Journal of Physiology. Endocrinology and Metabolism 2001, 280:E23-E30.
2. Basu R., Barosa C., Jones J., Dube S., Carter R., Basu A., et al. Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. The Journal of Clinical Endocrinology and Metabolism 2013, 98:E409-E417.
3. Gastaldelli A., Toschi E., Pettiti M., Frascerra S., Quinones-Galvan A., Sironi A.M., et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 2001, 50:1807-1812.
4. Rizza R.A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 2010, 59:2697-2707.
5. Konopelska S., Kienitz T., Quinkler M. Downregulation of hepatic glucose-6-phosphatase-alpha in patients with hepatic steatosis. Obesity (Silver Spring) 2011, 19:2322-2326.
6. Samuel V.T., Beddow S.A., Iwasaki T., Zhang X.M., Chu X., Still C.D., et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12121-12126.
7. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochemical Journal 2008, 414:1-18.
8. Caro J.F., Triester S., Patel V.K., Tapscott E.B., Frazier N.L., Dohm G.L. Liver glucokinase: decreased activity in patients with type II diabetes. Hormone and Metabolic Research= Hormon- und Stoffwechselforschung= Hormones et metabolisme 1995, 27:19-22.
9. Clore J.N., Stillman J., Sugerman H. Glucose-6-phosphatase flux invitro is increased in type 2 diabetes. Diabetes 2000, 49:969-974.
10. Ferris S.A. Hepatic glucokinase activity in human diabetics and nondiabetics. Metabolism 1964, 13:1478-1481.
11. Basu A., Basu R., Shah P., Vella A., Johnson C.M., Jensen M., et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 2001, 50:1351-1362.
12. Basu A., Basu R., Shah P., Vella A., Johnson C.M., Nair K.S., et al. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 2000, 49:272-283.
13. Velho G., Petersen K.F., Perseghin G., Hwang J.H., Rothman D.L., Pueyo M.E., et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. The Journal of Clinical Investigation 1996, 98:1755-1761.
14. Torres T.P., Catlin R.L., Chan R., Fujimoto Y., Sasaki N., Printz R.L., et al. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes 2009, 58:78-86.
15. Ueta K., O'Brien T.P., McCoy G.A., Kim K., Healey E.C., Farmer T.D., et al. Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity. American Journal of Physiology. Endocrinology and Metabolism 2014, 306:E1225-E1238.
16. Iynedjian P.B., Marie S., Gjinovci A., Genin B., Deng S.P., Buhler L., et al. Glucokinase and cytosolic phosphoenolpyruvate carboxykinase (GTP) in the human liver. Regulation of gene expression in cultured hepatocytes. The Journal of Clinical Investigation 1995, 95:1966-1973.
17. Lin H.V., Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metabolism 2011, 14:9-19.
18. Hirota K., Sakamaki J., Ishida J., Shimamoto Y., Nishihara S., Kodama N., et al. Acombination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. The Journal of Biological Chemistry 2008, 283:32432-32441.
19. Xiong X., Tao R., DePinho R.A., Dong X.C. Deletion of hepatic FoxO1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of gluconeogenesis and upregulation of glycolysis. PLoS One 2013, 8:e74340.
20. Zhang W., Patil S., Chauhan B., Guo S., Powell D.R., Le J., et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. The Journal of Biological Chemistry 2006, 281:10105-10117.
21. Haeusler R.A., Hartil K., Vaitheesvaran B., Arrieta-Cruz I., Knight C.M., Cook J.R., et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nature Communications 2014, 5:5190.
22. Banks A.S., Kim-Muller J.Y., Mastracci T.L., Kofler N.M., Qiang L., Haeusler R.A., et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice. Cell Metabolism 2011, 14:587-597.
23. Haeusler R.A., Han S., Accili D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. The Journal of Biological Chemistry 2010, 285:26861-26868.
24. Matschinsky F.M. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?. Trends in Pharmacological Sciences 2013, 34:90-99.
25. Peter A., Stefan N., Cegan A., Walenta M., Wagner S., Konigsrainer A., et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. The Journal of Clinical Endocrinology and Metabolism 2011, 96:E1126-E1130.
26. Schwarz J.M., Linfoot P., Dare D., Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. American Journal of Clinical Nutrition 2003, 77:43-50.
27. Vedala A., Wang W., Neese R.A., Christiansen M.P., Hellerstein M.K. Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. The Journal of Lipid Research 2006, 47:2562-2574.
28. Barrows B.R., Parks E.J. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. The Journal of Clinical Endocrinology and Metabolism 2006, 91:1446-1452.
29. Groop L.C., Bonadonna R.C., DelPrato S., Ratheiser K., Zyck K., Ferrannini E., et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. Journal of Clinical Investigation 1989, 84:205-213.
30. Bevilacqua S., Buzzigoli G., Bonadonna R., Brandi L.S., Oleggini M., Boni C., et al. Operation of Randle's cycle in patients with NIDDM. Diabetes 1990, 39:383-389.